Trial Profile
A Phase II Clinical Study of GC1118 in Recurrent Glioblastoma Patients With High Epidermal Growth Factor Receptor (EGFR) Amplification
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs GC 1118A (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 11 May 2023 Status changed from recruiting to completed.
- 14 Jul 2020 Planned End Date changed from 21 Jul 2020 to 31 Jul 2021.
- 14 Jul 2020 Planned primary completion date changed from 21 Jan 2020 to 31 Dec 2020.